Pulse nav.journalClub Tendencias Explorar Preguntas Investigadores

Download the App

Join discussions, follow papers, and never miss your next session.

© Synapse Social LLC, 2026Política de privacidad

Inicio Explorar nav.journalClub Tendencias

⌘+K

Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency | Synapse

March 30, 2025Open Access

Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

ClinicalTrials.gov Identifier: NCT03036462.

Leer artículo completoexternamente

Me gusta

Guardar

Compartir

Ver artículo completo

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Anker et al. (Sun,) studied this question.

synapsesocial.com/papers/69d97d70387cf7069868448a https://doi.org/https://doi.org/10.1001/jama.2025.3833

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Rationale and Design of the FAIR-HF2-DZHK05 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure2025 · 10 citations
2Defining iron replete status in patients with heart failure treated with intravenous iron2023 · 15 citations
3Ferric Carboxymaltose in Heart Failure with Iron Deficiency2023 · 216 citations
4Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron Deficiency2008 · 562 citations
5A New Equation to Estimate Glomerular Filtration Rate2009 · 25,665 citations